ClinicalTrials.gg
Active, not recruitingNCT04910022Updated Aug 19, 2025

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

A Phase 1/2 interventional study of NMS-03305293 and Temozolomide in Glioblastoma and Diffuse Glioma, sponsored by Nerviano Medical Sciences. Active, not recruiting at 18 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Nerviano Medical Sciences · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
98th of 1,155
150 · median 33
Started
2021
with 41 others
Phase 1/2
190 of 1,302
32 open now
Primary completion
2027-05
later than 148 of 322 live
Registered
1,041st of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 98th largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 42 that started in 2021, is one of 190 in phase 1/2, reaches primary completion later than 148 of the 322 other live ones, and was the 1,041st registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.

03

Conditions studied

  • Glioblastoma
  • Diffuse Glioma

Browse trials for

Keywords

  • IDH wild type
  • PARP inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 1

    1. confirmed diagnosis of an intracranial diffuse glioma (i.e. diffuse astrocytoma, oligodendroglioma or glioblastoma). Sponsor may opt to restrict enrollment based on MGMT status, tumor type, tumor measurability or apply restriction on time to first relapse.
    2. Patients at first radiographic relapse after chemotherapy including temozolomide as long as no more than 12 cycles of temozolomide were administered.
    3. Patients may have been operated for recurrence. If operated:

      • residual and after surgery is not required but pathology must have confirmed tumor recurrence.
      • a post-surgery MRI should be available within 48 hours following surgery.
      • surgery completed at least 2 weeks before enrolment and patient clinical status should not be worsened respect to pre-surgery condition
  • Backfill cohorts

    1. Histologically confirmed diagnosis of Glioblastoma, IDH-wildtype as per WHO 2021 classification, including IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes or c-IMPACT-NOW 3 definition including diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO Grade 4. IDH1 status must be assessed locally by immunohistochemistry (IHC). If IHC is performed and is negative, and patient is \< 55 years old, sequencing or a PCR-based validated test must be performed to exclude other IDH1 or IDH2 most frequent mutations. Sponsor may opt to restrict enrollment based on MGMT status or apply restriction on time to first relapse.
    2. Patients must have measurable disease and meet standard of care resection, if indicated, and irradiation, if indicated, with concomitant temozolomide plus up to 6 cycles of adjuvant temozolomide consistent with local standards of care.
    3. Patients may have been operated for recurrence. If operated:

      • residual and measurable disease after surgery is required
      • a post-surgery MRI should be available within 48 hours following surgery
      • surgery completed at least 2 weeks before enrolment and patient clinical status should not be worsened respect to pre-surgery condition.
  • Phase 2

    1. Histologically confirmed diagnosis of Glioblastoma, IDH-wildtype as per WHO 2021 classification, including IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes or c-IMPACTNOW 3 definition including diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO Grade 4. IDH1 status must be assessed locally by immunohistochemistry (IHC). If IHC is performed and is negative, and patient is \< 55 years old, sequencing or a PCR-based validated test must be performed to exclude other IDH1 or IDH2 most frequent mutations. Sponsor may opt to restrict enrollment based on MGMT status or apply restriction on time to first relapse.
    2. Patients must have measurable disease at first radiographic relapse after initial standard therapy including temozolomide as long as no more than 6 cycles of adjuvant temozolomide were administered and provided that patient completed standard of care concurrent temozolomide and the radiation therapy; multiple surgeries are allowed as long as patient is at first relapse and TMZ was administered as standard of care.
    3. Patients may have been operated for recurrence. If operated:

      • residual and measurable disease after surgery is required
      • a post-surgery MRI should be available within 48 hours following surgery
      • surgery completed at least 2 weeks before enrolment and patient clinical status should not be worsened respect to pre-surgery condition.
  • Phase 1 (including backfill) and Phase 2

    4. For non-operated patients with measurable disease in Phase I, for backfill and for all patients in Phase 2, recurrent disease must be defined by at least one bidimensionally measurable contrast-enhancing lesion with clearly defined margins with minimal diameters of 10 mm, visible on 2 or more axial slices 5 mm apart, based on MRI scan done within two weeks prior to enrolment.

    5. Patients on should have stable or decreasing dose of steroids for 7 days prior to the baseline MRI scan.

    6. of at least 3 months.

    7. Able to undergo brain MRI scans with IV gadolinium.

    8. No evidence of symptomatic and acute intratumoral hemorrhage on MRI. Patients with MRI demonstrating old hemorrhage or subacute blood after a neurosurgical procedure ( or resection) are eligible.

    9. Sufficient tissue representative of the disease available for central MGMT promoter methylation status (Phase I and II) and IDH status evaluation (Phase I).

    10. Male or female patients with age ≥ 18 years.

    11. performance status ≤2.

    12. Signed and dated IEC or IRB-approved .

    13. Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy to (Version 5.0) Grade ≤ 1 or to the baseline laboratory values as defined in Inclusion Criterion Number 14.

    14. Baseline laboratory values fulfilling the requirements declared into the Protocol

    15. Patients must use highly effective or true abstinence. Female patients of must agree to use effective contraception or abstinence during the period of therapy and in the following 6 months plus 5x NMS-03305293 half-life (3 days) after discontinuation of study treatment. Being NMS-03305293 a potential perpetrator, hormonal contraception may lose efficacy while on treatment with NMS-03305293, therefore this should be taken into account. Male patients must be surgically sterile or must agree to use highly effective contraception or true abstinence during the period of therapy and in the following 90 days plus 5x NMS-03305293 half-life (3 days) after discontinuation of study treatment.

    16. Ability to swallow capsules intact (without chewing, crushing, or opening).

    17. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures.

Exclusion criteria

Exclusion Criteria:

  1. Current enrollment in another interventional clinical trial.
  2. Current treatment with other anticancer agents or devices, or treatment at recurrence with carmustine wafer implants and proteasome inhibitors.
  3. Previous treatment with PCV (procarbazine, lomustine and vincristine) or any of its components, carmustine wafer implants, or bevacizumab.
  4. Previous treatment with PARP inhibitors.
  5. Major surgery, other than surgery for recurrent diffuse glioma, within 4 weeks prior to treatment.
  6. Standard radiotherapy within the three months (12 weeks) prior to the diagnosis of progression unless the progression is clearly outside the radiation field (eg, beyond the high-dose region or 80% isodose line) or unless the recurrence is proven.
  7. Prior radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or brachytherapy, unless the recurrence is histologically proven.
  8. Use of full-dose anticoagulants unless the or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks before enrollment
  9. Treatment with concomitant medications known to be sensitive substrates of CYP2D6 and CYP2C19 that cannot be replaced with another treatment.
  10. Treatment with enzyme-inducing anti-epileptic drugs (EIAED). Patients may be on non-EIAED or not be taking any anti-epileptic drugs. Patients previously on EIAED must be fully switched to non-EIAED at least 2 weeks prior to enrolment.
  11. Pregnant or breast-feeding women.
  12. Known to any component of NMS-03305293 or TMZ drug formulations.
  13. Known active infections (bacterial, fungal, viral including positivity) requiring systemic treatment.
  14. Patients with ≥460 milliseconds for women, ≥450 milliseconds for men or with risk factors for torsade de pointes (e.g., uncontrolled heart failure, uncontrolled hypokalemia, history of prolonged QTc interval or family history of long QT syndrome). For patients receiving treatment with concomitant medications known to prolong the QTc interval, replacement with another treatment prior to enrollment is mandatory. If concomitant use of anti-emetics is considered essential for the care of the patients, instruction in protocol will be followed.
  15. Active gastrointestinal disease (e.g., documented gastrointestinal ulcer, Crohn's disease, ulcerative colitis, or short gut syndrome) or other syndromes that would impact on drug absorption.
  16. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or , active bleeding disorder.
  17. Prior invasive (except for non melanoma skin cancer, carcinoma in situ or localized cancer) unless the patient has been disease-free and off therapy for that disease for ≥ 3 years.
  18. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    NMS-03305293 +TMZ

    Phase 1 Dose Escalation: All patients will receive NMS-03305293 and temozolomide (TMZ) administered orally (NMS-03305293 once or twice daily on days 1-7 or 28 consecutive days from Day 1 to Day 28; TMZ once daily on days 1-5;) in repeated 4-week cycles aimed at defining the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Doses (RP2Ds) of NMS-03305293 in combination with TMZ. Each cycle is 28 days. Phase 2: Once the RP2D is defined, the patients will receive TMZ daily on days 1-5 in combination with NMS-03305293 at the RP2D on days 1-7 or on days 1-28 every 28 days. Backfill cohorts: additional patients may be treated with TMZ daily on days 1-5 and NMS-03305293 at different dose levels/schedules that have been previously assessed and determined to be safe, in order to properly characterize the exposure relationship over a range of doses/schedules. The backfill cohorts may run in parallel.

    Drug: NMS-03305293 · Drug: Temozolomide

Interventions

  • Route of administration: Oral

  • Route of administration: Oral Commercially available temozolomide

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants with first-cycle dose limiting toxicity

    Time frame: Time interval between the first dose administration in Cycle 1 and the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to drug related toxicity

  2. Phase 2: Objective Response Rate

    Objective Response Rate (ORR), calculated as the proportion of evaluable patients who have achieved, as best overall response (BOR), confirmed complete response (CR) or partial response (PR) through central retrospective assessment of RANO criteria

    Time frame: From the date of first response up to data cut-off (approximately 18 months)

Secondary outcomes

  1. Number of participants with Adverse Events (AEs)

    Safety will be assessed by adverse events (AEs), which include clinically significant abnormalities identified during a medical test (e.g. laboratory tests, electrocardiogram, vital signs, physical examinations). AEs will be coded by Medical Dictionary for Regulatory Activities (MedDRA) and their severity will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE, version 5.0).The analysis will focus on the events reported after the start of treatment (treatment emergent adverse events).

    Time frame: From the Informed Consent signature to 28 days after the last dose of study treatment administration

  2. Maximum concentration (Cmax) of NMS-03305293 and possible identified metabolites (if appropriate) after single and multiple doses of drug

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Phase 1 and backfill cohorts: Cycle 1 (each cycle is 28 days) on Days 1, 2, 5, 6 and 8; Cycle 2 on Days 5 and 15 (day 15 only if 28 days schedule). Phase 2: Cycle 1 (Days 1 and 5), Cycle 2 (Day 5) and Cycle 3 or Cycle 4 (Day 5)

  3. Time to observed Cmax (Tmax) of NMS-03305293 and possible identified metabolites (if appropriate) after single and multiple doses of drug

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Phase 1 and backfill cohorts: Cycle 1 (each cycle is 28 days) on Days 1, 2, 5, 6 and 8; Cycle 2 on Days 5 and 15 (day 15 only if 28 days schedule). Phase 2: Cycle 1 (Days 1 and 5), Cycle 2 (Day 5) and Cycle 3 or Cycle 4 (Day 5)

  4. Area under the concentration-time curve up to the last detectable plasma concentration (AUClast) of NMS-03305293 and possible identified metabolites (if appropriate) after single and repeated dose of drug.

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Phase 1 and backfill cohorts: Cycle 1 (each cycle is 28 days) on Days 1, 2, 5, 6 and 8; Cycle 2 on Days 5 and 15 (day 15 only if 28 days schedule). Phase 2: Cycle 1 (Days 1 and 5), Cycle 2 (Day 5) and Cycle 3 or Cycle 4 (Day 5)

  5. Terminal elimination half-life (t1/2) of NMS-03305293 and possible identified metabolites (if appropriate) after single and multiple doses of drug

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Phase 1 and backfill cohorts: Cycle 1 (each cycle is 28 days) on Days 1, 2, 5, 6 and 8; Cycle 2 on Days 5 and 15 (day 15 only if 28 days schedule). Phase 2: Cycle 1 (Days 1 and 5), Cycle 2 (Day 5) and Cycle 3 or Cycle 4 (Day 5)

  6. Area under the plasma concentration vs. time curve to infinity (AUCinf) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug.

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Phase 1 and backfill cohorts: Cycle 1 (each cycle is 28 days) on Days 1, 2, 5, 6 and 8; Cycle 2 on Days 5 and 15 (day 15 only if 28 days schedule). Phase 2: Cycle 1 (Days 1 and 5), Cycle 2 (Day 5) and Cycle 3 or Cycle 4 (Day 5)

  7. Accumulation ratio (Rac) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug.

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Phase 1 and backfill cohorts: Cycle 1 (each cycle is 28 days) on Days 1, 2, 5, 6 and 8; Cycle 2 on Days 5 and 15 (day 15 only if 28 days schedule). Phase 2: Cycle 1 (Days 1 and 5), Cycle 2 (Day 5) and Cycle 3 or Cycle 4 (Day 5)

  8. Oral plasma clearance (CL/F) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Phase 1 and backfill cohorts: Cycle 1 (each cycle is 28 days) on Days 1, 2, 5, 6 and 8; Cycle 2 on Days 5 and 15 (day 15 only if 28 days schedule). Phase 2: Cycle 1 (Days 1 and 5), Cycle 2 (Day 5) and Cycle 3 or Cycle 4 (Day 5)

  9. Apparent volume of distribution (Vd/F) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug

    Plasma samples will be collected and used for pharmacokinetics assessments

    Time frame: Phase 1 and backfill cohorts: Cycle 1 (each cycle is 28 days) on Days 1, 2, 5, 6 and 8; Cycle 2 on Days 5 and 15 (day 15 only if 28 days schedule). Phase 2: Cycle 1 (Days 1 and 5), Cycle 2 (Day 5) and Cycle 3 or Cycle 4 (Day 5)

  10. Phase 1: Renal clearance of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug

    Urine samples will be collected in patients treated in the phase 1 and in backfill cohorts and used for pharmacokinetics assessments

    Time frame: At baseline, at Cycle 1 (each cycle is 28 days) Day 5 at different timepoints

  11. Phase 1: Cumulative amount recovered unchanged in the urine (Ae) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug

    Urine samples will be collected in patients treated in the phase 1 and in backfill cohorts and used for pharmacokinetics assessments

    Time frame: At baseline, at Cycle 1 (each cycle is 28 days) Day 5 at different timepoints

  12. Phase 1: Cumulative amount recovered unchanged in the urine expressed as a fraction of administered dose (Ae%) of NMS-03305293 and possible identified metabolites (if appropriate) after multiple doses of drug

    Urine samples will be collected in patients treated in the phase 1 and in backfill cohorts and used for pharmacokinetics assessments

    Time frame: At baseline, at Cycle 1 (each cycle is 28 days) Day 5 at different timepoints.

  13. Phase 1: Objective Tumor Response

    Complete and partial responses will be assessed according to RANO criteria

    Time frame: At baseline, every 8 weeks until disease progression or start of a new anticancer therapy (approximately 18 months).

  14. Phase 1: Duration of Response

    Duration of response will be calculated from the date of either first CR or PR until the date of documented progression for patients who achieved CR or PR. Patients who died without report of progression will be considered non-events and censored at their last disease-free assessment date

    Time frame: From the date of first response up to data cut-off (approximately 18 months).

  15. Phase 1: Progression Free Survival

    Progression Free Survival will be calculated from the date of treatment initiation to the date of first documentation of disease progression, or death due to any cause, whichever occurs first

    Time frame: From the date of treatment initiation up to data cut-off (approximately 18 months)

  16. Phase 2: Duration of response (DoR) through central retrospective assessment of RANO criteria

    Duration of response will be calculated from the date of either first CR or PR until the date of documented progression for patients who achieved CR or PR. Patients who died without report of progression will be considered non-events and censored at their last disease-free assessment date

    Time frame: From the date of first response up to data cut-off (approximately 18 months).

  17. Phase 2: Progression-free survival (PFS)

    Progression Free Survival will be calculated from the date of treatment initiation to the date of first documentation of disease progression, or death due to any cause, whichever occurs first

    Time frame: From the date of treatment initiation up to data cut-off (approximately 18 months)

  18. Phase 2: 6-month PFS Rate

    Percentage of patients progressive-free at 6 months from treatment initiation

    Time frame: From date of treatment initiation until the date of first documentation of progression or death for any cause, whichever occurs first, assessed up to 6 months

  19. Phase 2: 9 and 12-Months Overall Survival Rates

    Percentage of patients alive at 9 and 12 months from treatment initiation.

    Time frame: From the date of treatment initiation until the date of death from any cause, assessed up to 9 and 12 months.

  20. Overall Survival

    Overall Survival will be calculated from the date of treatment initiation to the date of death due to any cause

    Time frame: From the date of treatment initiation up to data cut-off (approximately 24 months)

07

Study locations

18 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for May 2027, 65 months after the start.

Of 53 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's planned 65 months is above that.

Counting every sponsor, half of 138 studies reached it within 68 months; a quarter within 47 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2021
First posted
Jun 2, 2021
StartActual
Dec 1, 2021
Primary completionEst.
May 30, 2027
CompletionEst.
Sep 7, 2027
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04910022
Lead sponsor
Nerviano Medical Sciences
Responsible party
Sponsor
First posted
Jun 2, 2021
Start date
Dec 1, 2021
Primary completion
May 30, 2027 (estimated)
Completion
Sep 7, 2027 (estimated)
Last update
Aug 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itareparib

Start the discussion